Suven Pharmaceuticals Limited
NSE:SUVENPHAR.NS
1078 (INR) • At close May 16, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,071.5 | 2,577.2 | 2,306.9 | 2,529.304 | 2,198.196 | 2,310.537 | 3,475.501 | 3,693.562 | 3,537.717 | 2,784.018 | 3,387.991 | 3,334.289 | 3,915.853 | 3,009.883 | 2,638.013 | 2,293.823 | 2,749.332 | 2,373.881 | 2,382.324 | 1,579.169 | 1,787.062 | 2,729.276 | 1,973.914 | 2,393.404 | 1,269.152 |
| Cost of Revenue
| 556.3 | 520.6 | 1,497 | 1,768.942 | 1,051.419 | 868.819 | 1,335.469 | 1,569.001 | 1,570.011 | 1,321.176 | 1,394.037 | 1,374.742 | 1,656.985 | 1,363.144 | 1,155.988 | 1,205.126 | 1,017.253 | 1,033.294 | 946.362 | 690.709 | 708.964 | 1,175.167 | 662.927 | 967.845 | 544.009 |
| Gross Profit
| 2,515.2 | 2,056.6 | 809.9 | 760.362 | 1,146.777 | 1,441.718 | 2,140.032 | 2,124.561 | 1,967.706 | 1,462.842 | 1,993.954 | 1,959.547 | 2,258.868 | 1,646.739 | 1,482.025 | 1,088.697 | 1,732.079 | 1,340.587 | 1,435.962 | 888.46 | 1,078.098 | 1,554.109 | 1,310.987 | 1,425.559 | 725.143 |
| Gross Profit Ratio
| 0.819 | 0.798 | 0.351 | 0.301 | 0.522 | 0.624 | 0.616 | 0.575 | 0.556 | 0.525 | 0.589 | 0.588 | 0.577 | 0.547 | 0.562 | 0.475 | 0.63 | 0.565 | 0.603 | 0.563 | 0.603 | 0.569 | 0.664 | 0.596 | 0.571 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 22.759 | 22.822 | 44.739 | 20.88 | 20.09 | 22.698 | 20.746 | 22.323 | 21.442 | 21.885 | 36.694 | 23.524 | 15.063 | 26.585 | 38.142 | 30.785 | 34.079 | 26.915 | 52.943 | 27.378 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 164.609 | 0 | 0 | 0 | 122.774 | 0 | 0 | 0 | 311.281 | 0 | 0 | 0 | 95.779 | 0 | 0 | 0 | 181.752 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 34.775 | 0 | 0 | 0 | 34.893 | 0 | 0 | 0 | 18.833 | 0 | 0 | 0 | 18.369 | 0 | 0 | 0 | 36.037 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 0 | 0 | 456.2 | 199.384 | 144.185 | 131.598 | 287.44 | 157.667 | 181.306 | 156.824 | 265.856 | 330.114 | 250.087 | 231.943 | 100.818 | 114.148 | 213.471 | 209.29 | 174.442 | 217.789 | 154.208 | 152.579 | 170.487 | 162.777 | 0 |
| Other Expenses
| 1,541.7 | 2,056.6 | 0 | 170.537 | 143.446 | 198.417 | 106.651 | 113.995 | 130.112 | 109.2 | 110.331 | -740.383 | 646.851 | 50.411 | 57.829 | -98.901 | 48.429 | 3.568 | 57.391 | -125.184 | 48.875 | 54.452 | 24.446 | 235.741 | 1.857 |
| Operating Expenses
| 1,541.7 | 2,056.6 | 456.2 | 199.384 | 622.85 | 581.024 | 595.787 | 553.361 | 623.148 | 584.353 | 600.178 | 468.572 | 503.723 | 520.759 | 425.864 | 228.995 | 438.192 | 430.692 | 385.782 | 183.88 | 337.637 | 354.598 | 341.38 | 235.741 | 285.134 |
| Operating Income
| 973.5 | 870.5 | 943.9 | 560.978 | 667.373 | 1,059.111 | 1,544.245 | 1,685.195 | 1,474.67 | 987.689 | 1,393.776 | 1,478.991 | 1,755.145 | 1,125.98 | 1,056.161 | 859.702 | 1,293.887 | 909.895 | 1,050.18 | 704.58 | 740.461 | 1,199.511 | 969.607 | 1,189.818 | 440.009 |
| Operating Income Ratio
| 0.317 | 0.338 | 0.409 | 0.222 | 0.304 | 0.458 | 0.444 | 0.456 | 0.417 | 0.355 | 0.411 | 0.444 | 0.448 | 0.374 | 0.4 | 0.375 | 0.471 | 0.383 | 0.441 | 0.446 | 0.414 | 0.439 | 0.491 | 0.497 | 0.347 |
| Total Other Income Expenses Net
| 123.8 | 124.5 | -113 | 147.541 | -140.947 | -57.128 | 95.186 | 15.928 | -187.411 | -170.863 | 95.815 | 118.116 | 639.434 | 213.293 | 273.064 | 8.335 | -17.024 | -124.795 | -52.05 | 91.414 | 36.378 | 45.431 | 159.917 | -42.555 | -8.601 |
| Income Before Tax
| 1,097.3 | 995 | 830.9 | 708.519 | 654.683 | 1,054.083 | 1,639.431 | 1,662.109 | 1,460.843 | 984.755 | 1,489.591 | 1,612.821 | 2,394.579 | 1,339.273 | 1,329.225 | 1,054.697 | 1,474.999 | 968.36 | 1,178.685 | 893.813 | 776.839 | 1,244.942 | 1,129.524 | 1,147.263 | 431.408 |
| Income Before Tax Ratio
| 0.357 | 0.386 | 0.36 | 0.28 | 0.298 | 0.456 | 0.472 | 0.45 | 0.413 | 0.354 | 0.44 | 0.484 | 0.612 | 0.445 | 0.504 | 0.46 | 0.536 | 0.408 | 0.495 | 0.566 | 0.435 | 0.456 | 0.572 | 0.479 | 0.34 |
| Income Tax Expense
| 264.4 | 175.2 | 223.2 | 174.787 | 187.148 | 258.442 | 433.532 | 422.396 | 383.637 | 264.192 | 414.17 | 696.142 | 793.889 | 369.425 | 278.394 | 223.538 | 338.746 | 227.57 | 263.469 | 151.99 | 197.735 | 314.894 | 210.482 | 399.033 | 86.895 |
| Net Income
| 828.8 | 819.8 | 607.7 | 533.73 | 467.535 | 795.641 | 1,206 | 1,239.713 | 1,077.206 | 720.563 | 1,075.421 | 916.68 | 1,600.69 | 969.848 | 1,050.831 | 831.159 | 1,136.253 | 740.79 | 915.216 | 741.823 | 579.104 | 930.048 | 919.042 | 748.23 | 344.513 |
| Net Income Ratio
| 0.27 | 0.318 | 0.263 | 0.211 | 0.213 | 0.344 | 0.347 | 0.336 | 0.304 | 0.259 | 0.317 | 0.275 | 0.409 | 0.322 | 0.398 | 0.362 | 0.413 | 0.312 | 0.384 | 0.47 | 0.324 | 0.341 | 0.466 | 0.313 | 0.271 |
| EPS
| 3.26 | 3.23 | 2.39 | 2.1 | 1.84 | 3.13 | 4.74 | 4.87 | 4.23 | 2.83 | 4.22 | 3.6 | 6.29 | 3.81 | 4.13 | 3.26 | 4.46 | 2.91 | 3.6 | 2.91 | 2.27 | 3.65 | 3.61 | 2.94 | 1.35 |
| EPS Diluted
| 3.23 | 3.21 | 2.39 | 2.1 | 1.84 | 3.13 | 4.74 | 4.87 | 4.23 | 2.83 | 4.22 | 3.6 | 6.29 | 3.81 | 4.13 | 3.26 | 4.46 | 2.91 | 3.6 | 2.91 | 2.27 | 3.65 | 3.61 | 2.94 | 1.35 |
| EBITDA
| 1,334.1 | 1,181.3 | 799.3 | 903.976 | 794.891 | 1,178.03 | 1,776.308 | 1,804.778 | 1,597.06 | 1,107.994 | 1,619.153 | 1,738.916 | 2,507.056 | 1,268.161 | 1,203.923 | 969.887 | 1,429.891 | 988.465 | 1,178.205 | 1,005.016 | 845.33 | 1,344.527 | 1,049.026 | 1,213.553 | 497.267 |
| EBITDA Ratio
| 0.434 | 0.458 | 0.346 | 0.357 | 0.362 | 0.51 | 0.511 | 0.489 | 0.451 | 0.398 | 0.478 | 0.522 | 0.64 | 0.421 | 0.456 | 0.423 | 0.52 | 0.416 | 0.495 | 0.636 | 0.473 | 0.493 | 0.531 | 0.507 | 0.392 |